The Use of Nerve Conduction Study to Evaluate the Effects of Frozen Sock Treatment on Docetaxel-Induced Peripheral Neuropathy in Breast Cancer Patients: A Prospective Clinical Trial
Open Access
- 28 January 2025
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (3) , 864
Abstract
Background/Objectives: Docetaxel is a cytotoxic agent for the treatment of breast cancer, and its toxicities include peripheral neuropathy (PN). This study evaluated the ability of frozen sock (FS) treatment to prevent docetaxel-induced PN by performing nerve conduction study (NCS). Methods: From October 2017 to October 2018, 48 patients who had invasive carcinoma and were planned for docetaxel treatment every three weeks were evaluated. Patients wore a FS on the right foot, and the left foot was not protected by the FS during docetaxel infusion. Motor and sensory NCS as well as nail and skin toxicities were assessed. Results: The amplitude and velocity of the motor and sensory nerves significantly decreased after three months in both feet. Before and after three months of chemotherapy, the compound motor action potentials (CMAPs) for the right peroneal nerve were 7.64 ± 2.42 and 6.81 ± 2.21 mV, respectively (p < 0.001), and 7.13 ± 2.41 and 5.90 ± 2.24 mV, respectively (p < 0.001), for the left peroneal nerve. Reductions in the CMAP amplitude of the peroneal nerve were significantly lower in the right foot compared to the left foot (−9.58 vs. −16.8, p = 0.043). Application of the FS did not significantly decrease the overall incidence of skin and nail toxicity compared with the left foot during the study period (all p > 0.05). Conclusions: Docetaxel induced motor and sensory PN, but the use of a FS resulted in a smaller reduction in peroneal nerve amplification three months after the end of chemotherapy.Keywords
Funding Information
- Korea Breast Cancer Foundation (KBCF-2017C006)
This publication has 38 references indexed in Scilit:
- Efficacy of Siriraj, in-house-developed, frozen gloves for cold therapy reduction of chemotherapy-induced peripheral neuropathy in gynecological cancer patients: randomized controlled trialSupportive Care in Cancer, 2022
- Safety and tolerability of cryocompression as a method of enhanced limb hypothermia to reduce taxane-induced peripheral neuropathySupportive Care in Cancer, 2019
- Cold therapy to prevent paclitaxel-induced peripheral neuropathySupportive Care in Cancer, 2018
- Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505)Supportive Care in Cancer, 2016
- Cryotherapy for docetaxel-induced hand and nail toxicity: randomised control trialSupportive Care in Cancer, 2013
- Risk of docetaxel-induced peripheral neuropathy among 1,725 Danish patients with early stage breast cancerBreast Cancer Research and Treatment, 2013
- Degree of freezing does not affect efficacy of frozen gloves for prevention of docetaxel-induced nail toxicity in breast cancer patientsSupportive Care in Cancer, 2011
- A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CASupportive Care in Cancer, 2010
- Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02Supportive Care in Cancer, 2009
- Matched case‐control phase 2 study to evaluate the use of a frozen sock to prevent docetaxel‐induced onycholysis and cutaneous toxicity of the footCancer, 2008